Figure 1.

Antibody in lymphocyte secretion (ALS) IgA immune responses against ETVAX colonization factors (CFs) and LTB in (A) Swedish adults given 2 biweekly doses of ETVAX alone or ETVAX + 10 or 25 µg of double-mutant heat-labile toxin (dmLT) or placebo; (B) Bangladeshi adults given 2 biweekly doses of ETVAX alone or ETVAX + 10 µg of dmLT or placebo; and (C) Swedish adults given a single dose of ETVAX, including subjects who 1–2 years earlier had been given 2 doses of ETVAX alone or ETVAX + 10 µg of dmLT, and naive age-matched Swedish adults who previously had not been immunized with ETVAX. (A–C) Immune responses were determined as ≥2-fold rises in ALS antibody levels between pre- and postimmunization specimens collected on day 7 after the first day and 5–7 days (day 19–21) after the second dose or on days 4 or 5 and 7 after the single booster dose. Fold-rise responses are shown as geometric mean (bars) responses against the respective vaccine antigen for each study group; dots indicate individual responses; fold-rises in Figure 1A were determined as the maximal response after the first or second dose. Responder frequencies (RF) in vaccine and placebo recipients are indicated below the bars. Based on results from [6, 8, 9].